Active, not recruitingPhase 2NCT05822752
Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)
Studying Adult hepatocellular carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- AbbVie
- Principal Investigator
- ABBVIE INC.AbbVie
- Intervention
- Budigalimab(drug)
- Enrollment
- 130 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2026
Study locations (30)
- Arizona Oncology Associates, PC - NAHOA Prescott Valley /ID# 254313, Prescott Valley, Arizona, United States
- Highlands Oncology Group, PA /ID# 253158, Springdale, Arkansas, United States
- University of California, Los Angeles /ID# 253292, Los Angeles, California, United States
- UC Irvine /ID# 252707, Orange, California, United States
- California Pacific Medical Center - San Francisco - Webster Street /ID# 253291, San Francisco, California, United States
- Rocky Mountain Cancer Centers - Denver Midtwon /ID# 254163, Denver, Colorado, United States
- AdventHealth Orlando /ID# 252865, Orlando, Florida, United States
- The University of Chicago Medical Center /ID# 252870, Chicago, Illinois, United States
- Hematology/Oncology Clinic /ID# 253851, Baton Rouge, Louisiana, United States
- Dana-Farber Cancer Institute /ID# 252696, Boston, Massachusetts, United States
- Henry Ford Hospital /ID# 253342, Detroit, Michigan, United States
- Washington University-School of Medicine /ID# 252698, St Louis, Missouri, United States
- NYU Langone - Laura and Isaac Perlmutter Cancer Center /ID# 252708, New York, New York, United States
- Memorial Sloan Kettering Cancer Center-Koch Center /ID# 252705, New York, New York, United States
- Messino Cancer Center - Asheville /ID# 253888, Asheville, North Carolina, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05822752 on ClinicalTrials.govOther trials for Adult hepatocellular carcinoma
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONPHASE2NCT07441369Abemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases CancerFudan University
- RECRUITINGPHASE2NCT07175441Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular CarcinomaRiboscience, LLC.
- RECRUITINGPHASE2NCT07560488Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular CarcinomaTianjin Medical University Cancer Institute and Hospital
- RECRUITINGPHASE2NCT07010497A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Bevacizumab in Patients With Hepatocellular CarcinomaAsan Medical Center
- RECRUITINGPHASE1, PHASE2NCT07291076A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)Bristol-Myers Squibb
- RECRUITINGPHASE1, PHASE2NCT07500220Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCCBeijing Biotech
- RECRUITINGPHASE2NCT07413354Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular CarcinomaTongji Hospital
- RECRUITINGNANCT07365527Sonoporation and Tumor Microenvironment Response in Colorectal Liver MetastasesZealand University Hospital